Fan Lijun - Lotus Pharmaceuticals Independent Director
| LTUS Stock | USD 0.01 0 28.57% |
Director
Mr. Lijun Fan is Independent Director of Lotus Pharmaceuticals, Inc. He has served as President and CEO of Jolyvia International, Inc., which manufactures independent brand cosmetics and operates Jolyvia Beauty SPA national chain stores in China. From 2003 to 2009, he was the general manager and director of Jourdeness International Inc., where he was responsible for the expansion of directtoconsumer cosmetics and beauty chain SPA in China. Previously, from 1997 to 2003, he was the general manager and founder of Zhuhai Yi Sheng Development Co., a sales distributor for cosmetics and personal care products, and sales manager for Zhuhai Dong Da Biological Pharmaceutical Co.. Mr. Fan holds a BS degree in biology from Jinan University. Mr. Fans scientific, marketing and manufacturing experience and knowledge led to the conclusion he should serve on the Companys board of directors given the Companys business and structure. since 2010.
| Age | 41 |
| Tenure | 14 years |
| Phone | 615 310 2688 |
| Web | https://lotuspharmaceuticalsusa.com |
Lotus Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0456 % which means that it generated a profit of $0.0456 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0182 %, meaning that it created $0.0182 on every $100 dollars invested by stockholders. Lotus Pharmaceuticals' management efficiency ratios could be used to measure how well Lotus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Thierry Derez | SCOR PK | 60 | |
| Thomas Saunier | SCOR PK | 51 | |
| Daniel Valot | SCOR PK | 70 | |
| Guylaine Saucier | SCOR PK | 68 | |
| Wang Zhen | SCOR PK | 61 | |
| Andreas Brandstetter | SCOR PK | 45 | |
| Kevin Knoer | SCOR PK | 58 | |
| Claude Tendil | SCOR PK | 72 | |
| Kory Sorenson | SCOR PK | 49 | |
| Vanessa Marquette | SCOR PK | 46 | |
| Augustin Romanet | SCOR PK | 55 | |
| Peter Eckert | SCOR PK | 70 | |
| Vincent Foucart | SCOR PK | 39 | |
| Marguerite BerardAndrieu | SCOR PK | 40 | |
| Bruno Pfister | SCOR PK | 59 | |
| Guillaume Sarkozy | SCOR PK | 64 | |
| Gerard Andreck | SCOR PK | 71 | |
| Augustin Beaune | SCOR PK | 57 | |
| Jane WickerMiurin | SCOR PK | 59 | |
| Michele Aronvald | SCOR PK | 57 | |
| JeanMarc Raby | SCOR PK | 59 | |
Management Performance
| Return On Equity | 0.0182 | |||
| Return On Asset | 0.0456 |
Lotus Pharmaceuticals Leadership Team
Elected by the shareholders, the Lotus Pharmaceuticals' board of directors comprises two types of representatives: Lotus Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lotus. The board's role is to monitor Lotus Pharmaceuticals' management team and ensure that shareholders' interests are well served. Lotus Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lotus Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Li Zhaohui, Independent Director | ||
| Fan Lijun, Independent Director | ||
| Xing Shen, VP of Corporate Devel. | ||
| Yan Zeng, CFO and Principal Accounting Officer | ||
| Lu Jun, Director | ||
| Zhongyi Liu, Chairman of the Board and Presidentident, CEO | ||
| Zhong Liu, Chairman, Founder |
Lotus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Lotus Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0182 | |||
| Return On Asset | 0.0456 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.11 % | |||
| Current Valuation | 762.17 K | |||
| Shares Outstanding | 27.82 M | |||
| Price To Earning | 0.18 X | |||
| Price To Book | 0.01 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 72.7 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lotus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Complementary Tools for Lotus Pink Sheet analysis
When running Lotus Pharmaceuticals' price analysis, check to measure Lotus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lotus Pharmaceuticals is operating at the current time. Most of Lotus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lotus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lotus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lotus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |